Dupilumab (new indication: asthma bronchiale, patients aged ≥ 6 bis ≤ 11)

Subject:

• Active Substance: Dupilumab
• Name: Dupixent^®
• Therapeutic area: Asthma
• Pharmaceutical company: Sanofi-Aventis Deutschland GmbH

Time table:

• Start: 15.04.2022
• Final decision by G-BA: 06.10.2022

Final decision:

• No additional benefit proved